For Tuesday, February 7th
EGOH, EVCA, BMTI, FORC, OXGN, EFIR
Our Stocks to Watch today include Eagle Oil Holding Company Inc. (OTC: EGOH), Evcarco Inc. (OTC: EVCA), BioMimetic Therapeutics Inc. (NASDAQ: BMTI), Force Energy Corp. (OTCBB: FORC), OXiGENE Inc. (NASDAQ: OXGN) and EGPI Firecreek Inc. (OTCBB: EFIR).
STOCKS TO WATCH
EAGLE OIL HOLDING COMPANY INCORPORATED (OTC: EGOH)
"Up 57.58% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/EGOH.php
Eagle Oil (EGOH) is an independent, growth-oriented energy company engaged in the exploration and production of oil through the development of a repeatable, low geological risk, high potential project in the active East Texas oil and gas region. The Company owns a 78% working interest in 173 wells on its 927 acres located in the Historic Woodbine Oil Field. The Company's goal is to recondition and restore production at all of its wells. Engineering reports show that Eagle Oil's East Texas field contains over 12,000,000 barrels of recoverable oil.
EGOH News:
February 6 - Eagle Oil Announces Execution of Investor Relations Agreement
Eagle Oil Holding Company, Inc. (OTC: EGOH) (the "Company") announced the execution of an Investor Relations Agreement with Andrew Barwicki, Incorporated, a New York Company ("Barwicki").
Pursuant to the Agreement, Barwicki will introduce the new funding resources and investors necessary to enable the Company to recondition and restart up the wells at the Company's East Texas field. The Agreement represents another part of the Company's strategy to outsource the rebuilding of its corporate image, and increase its investor base. The Company expects work on the wells to commence as soon as funds become available. Barwicki will also assist with the Company's compliance requirements from the Texas Rail Road Commission.
ABOUT BARWICKI
Barwicki is a New York Public Relations and Investor Relations Company that has been active in the US public market, advising companies on funding opportunities and investor relations.
EVCARCO INCORPORATED (OTC: EVCA)
"Up 50.00% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/EVCA.php
Evarco Inc. is the Future Driven® automotive retail group dedicated to deploying a coast-to-coast network of environmentally friendly franchised dealerships and vehicles. Evarco is bringing to market the most advanced clean technologies available in plug-in electric, alternative fuel, and pre-owned hybrid vehicles. Evarco has developed a dealer network allowing growth into most US States by 2012.
EVCA News:
No recent stories.
BIOMIMETIC THERAPEUTICS INCORPORATED (NASDAQ: BMTI)
"Up 12.68% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/BMTI.php
BioMimetic Therapeutics is a biotechnology company specializing in the development and commercialization of clinically proven products to promote the healing of musculoskeletal injuries and diseases, including therapies for orthopedics, sports medicine and spine applications. All Augment branded products are based upon recombinant human platelet-derived growth factor (rhPDGF-BB), which is an engineered form of PDGF, one of the body's principal agents to stimulate and direct healing and regeneration. Through the commercialization of this patented technology, BioMimetic seeks to become the leading company in the field of regenerative medicine by providing new treatment options for the repair of bone, cartilage, tendons and ligaments.
BMTI News:
February 6 - BioMimetic Therapeutics, Inc. to Highlight Product Development Activities at ORS and AAOS Meetings
Company Announces Results of its Augment® Rotator Cuff Graft Clinical Trial
BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) announced results of its 30 patient Canadian Augment® Rotator Cuff Graft clinical trial. The goal of the randomized (2:1), controlled study was to assess the safety and performance of Augment Rotator Cuff for primary surgical treatment of full thickness rotator cuff tears as compared to standard surgical repair (suture alone).
The product achieved its primary safety endpoint, which was evaluated by a comparison of adverse events between the two treatment groups, and no device-related serious adverse events (SAEs) were reported. The results also indicated improvement in the clinical outcome assessments on DASH (Disabilities of Arm, Shoulder and Hand) and WORC (Western Ontario Rotator Cuff) index scores. Additionally, Augment Rotator Cuff was found to be user-friendly for the surgeons and required no additional operating room or anesthesia time over the current standard of care.
“We are extremely pleased to have successfully completed the pilot clinical trial evaluating Augment Rotator Cuff for the repair of large rotator cuff tears. Though only a small number of patients were evaluated, the clinical results, at this early stage, give me considerable cause for optimism,” said Robert Litchfield, MD, FRCSC, and principle investigator for the Augment Rotator Cuff pilot study. “In my view, rotator cuff repair is an area of orthopedic surgery that is currently not well satisfied, and I believe this innovative product has some unique advantages that, with continued positive results from a larger study, could prove to be a significant advancement in tendon regenerative repair.”
BioMimetic also announced its schedule of events at the Orthopedic Research Society (ORS) and the American Academy of Orthopedic Surgeons (AAOS) meetings. These meetings are being held consecutively in San Francisco, CA beginning February 4, 2012.
FORCE ENERGY CORPORATION (OTCBB: FORC)
"Up 18.57% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/FORC.php
Force Energy Corporation (FORC) is a Lithium, Rare Earth and Hydrocarbon Exploration and Development Company based in Denver, Colorado. Force Energy plans to explore and develop its Zoro 1 Lithium property located in the Snow Lake area of west-central Manitoba, Canada. Force Energy also maintains a 50% working interest in the Hayter Well, a Hydrocarbon well located in Alberta, Canada.
FORC News:
February 6 - Force Energy Obtains Drill Permit for Zoro 1 Property
Force Energy Corp. (OTCBB: FORC) (hereafter "Force", "the Company"), a junior Lithium and Rare Earth Metals mineral exploration company, is pleased to announce it has been granted a drill permit for the Zoro 1 Property by the Manitoba Conservation Office in Snow Lake, MB.
The permit authorizes Force to carry out a diamond drilling operation on the property. This initial diamond drilling program is a necessary evaluation of the Zoro 1 Property in order to examine the third dimension of the potential resource. Results of this program are intended to determine whether the confirmed historic resource of 1.7 million tons of lithium grading 0.95%Li20 can be mined economically.
"We are pleased to work with the efficient people of the Manitoba Conservation Office and thank them for their timeliness in authorizing this work permit," says Mr. Tim DeHerrera, president of Force Energy Corp. "The fact that the pegmatite and combined lithium comes to surface and has a historic resource established is extremely encouraging, and we look forward to examining core samples to confirm the third dimension of this resource and determine economic viability of the project."
OXIGENE INCORPORATED (NASDAQ: OXGN)
"Up 9.40% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/OXGN.php
OXiGENE, Inc. develops small-molecule therapeutics to treat cancer and eye diseases in the United States. It focuses on the development and commercialization of drug candidates that disrupt abnormal blood vessels associated with solid tumor progression and visual impairment in ocular diseases. The company's product ZYBRESTAT, is in Phase II/III pivotal registration study as a potential treatment for anaplastic thyroid cancer, as well as in Phase Ib and II clinical trials for other solid tumors, including non-small cell lung cancer, platinum resistant ovarian cancer, and head-and-neck cancer. It also develops a topical formulation of ZYBRESTAT for ophthalmological diseases and conditions, such as age-related macular degeneration. In addition, OXiGENE develops OXi4503, an ortho-quinone prodrug, which is in Phase I clinical trial for solid tumors. The company was founded in 1988 and is headquartered in Waltham, Massachusetts.
OXGN News:
February 6 - OXiGENE to Present at BIO CEO & Investor Conference
OXiGENE, Inc. (NASDAQ: OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced that Peter Langecker, MD, PhD, President and Chief Executive Officer, will present a corporate overview and business update at the BIO CEO & Investor Conference 2012 on February 13, 2012 at 1:30 pm ET at the Waldorf-Astoria Hotel in New York City.
To access the live audio webcast of the presentation, please log on through a link located in the Investors section of OXiGENE's website at www.oxigene.com, under the Events and Presentations tab. A replay of the webcast will be available one hour after the conclusion of the live event.
EGPI FIRECREEK INCORPORATED (OTCBB: EFIR)
"Up 42.86% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/EFIR.php
EGPI Firecreek, Inc.'s business and acquisition strategy is focused on producing oil and gas. The Company puts emphasis on acquiring existing fields with proven reserves or by the rehabilitation of oilfields with potentially high throughput. Through its wholly owned subsidiary Energy Producers, Inc., it acquires resource properties and inventories. Through its wholly owned subsidiary Chanwest Resources, LLC it operates as an oil and gas service business. EGPI Firecreek, Inc. is also planning to expand into producing energy through alternative energy sources through their recently acquired Arctic Solar Engineering subsidiary.
EFIR News:
No recent stories.
|
